Time-To-Loss Of Virologic Response Acceptable Endpoint For HIV Drugs-FDA
Executive Summary
Traditional approval of antiretroviral drugs may be based on clinical trials using a primary endpoint of time-to-loss of virologic response or on an endpoint of the proportion of patients whose HIV RNA levels fall below the acceptable assay level, a draft guidance released by FDA states.